# Dengue Vaccine Effectiveness: Results from a Six-Year Population-Based

#### **Cohort Study in Southern Brazil** 2

- **Keywords:** dengue, tetravalent dengue vaccine, vaccine effectiveness, population-based cohort, 3
- 4 **Brazil**

1

- Running title: Dengue vaccine effectiveness in Southern Brazil 5
- 6 Karin Regina Luhma, Silvia Emiko Shimakuraa, Sonia Mara Rabonia, Magda Clara Vieira da Costa-
- 7 Ribeiro<sup>a</sup>, Fredi Alexander Diaz-Quijano<sup>b</sup>, Angela Maron de Mello<sup>c</sup>, Lineu Roberto da Silva<sup>a</sup>,
- 8 Marilene da Cruz Magalhães Buffon<sup>a</sup>, Eliane Mara Cesário Pereira Maluf<sup>a</sup>, Gabriel Graeff<sup>d</sup>, Clara
- 9 Preto<sup>a</sup>, Gustavo Araújo de Almeida<sup>a</sup>, Gabriela Amanda de Sousa<sup>a</sup>, Elias Teixeira Krainski<sup>a</sup>, Allan
- 10 Arnold Evans<sup>a,</sup> Denise Siqueira de Carvalho<sup>a\*</sup>
- a Universidade Federal do Paraná (UFPR), Curitiba, Brazil 11
- 12 Address: Rua Padre Camargo, 280 - Alto da Glória, Curitiba - PR, 80060-240, Brazil
- b Universidade de São Paulo (USP), São Paulo, Brazil 13
- Address: Av. Dr. Arnaldo, 715 São Paulo/SP, 01246-904, Brazil 14
- 15 c – Health Ministry, Curitiba, Brazil
- Address: Av. Cândido Lopes, 208, 8º andar, sala 804 Centro, Curitiba PR, 80020-060, 16
- 17 **Brazil**
- d Faculdade UNISE, Campo Largo, Paraná, Brazil 18
- Address: R. XV de Novembro, 1609 Centro, Campo Largo PR, 83601-030, Brazil 19
- \*Corresponding author: 20
- 21 Denise Sigueira de Carvalho<sup>a</sup> (PhD Preventive Medicine – FM/USP)
- Address: Rua Padre Camargo, 280 Alto da Glória, Curitiba PR, 80060-240, Brazil 22
- Universidade Federal do Paraná (UFPR), Curitiba, Brazil 23
- Phone number: +55 41 999710498 Email: denisecarvalho@ufpr.br
  NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 24

- 25 **Author Contributions Statement**
- K.R.L., S.E.S., S.M.R.: conceptualization, methodology, data collection, analysis, 26
- interpretation, supervision, article revising and editing. M.C.V.C-R., F.A.D-Q analysis, 27
- 28 interpretation and article drafting. A.M.M, L.R.S., M.C.M.B., E.M.C.P.M.: methodology, data
- collection and article drafting. G.G., E.T.K.: data curation and analysis. C.P., G.A.A., G.A.S., 29
- 30 A.A.E.: investigation, article drafting and article editing. D.S.C: conceptualization,
- methodology, analysis, interpretation, and article revising and editing, funding acquisition and 31
- 32 project administration. All authors approved the final version of the manuscript.

#### **ABSTRACT**

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

57

The alarming growth of dengue worldwide and its social and economic impact have demanded more effective responses for its prevention and control. Currently, the first vaccine approved in Brazil for its prevention, Dengyaxia®, was administered to a target population of around 500,000 residents in southern Brazil. This study reports its effectiveness after a six-year follow-up period from August 2016 to July 2022. Dengue vaccination campaign was carried out in a target population of individuals aged 15–27 in 28 municipalities and 9–44 years in the other two. In this population-based cohort study, exposure to the vaccine included groups with different numbers of doses and adherence to the complete schedule. The primary outcome was probable dengue case. Other endpoints included laboratoryconfirmed dengue, serotype, dengue with warning signs or severe illness, and hospitalization. Approximately 60.4% of the participants received at least one vaccine dose. A total of 50,658 probable dengue cases (PDC) were notified of which 15,131 were laboratory-confirmed dengue cases. Overall effectiveness for at least one dose was 33.7% (95% CI: 32.5-34.9) for PDC and 20.1% (95% confidence interval [CI]: 17.1–22.9) for laboratory-confirmed cases. Greater vaccine effectiveness was observed in older individuals and for the DENV-4 and DENV-1 serotypes. The vaccine showed no effectiveness against DENV-2; no DENV-3 cases occurred. A lower hospitalization rate was observed among the vaccinated group. Differences in the incidence of severe dengue cases and warning signs could not draw a definite conclusion. Vaccination was associated with a one-third reduction in the incidence of probable dengue cases. By serotypes, the reduction was significant only for DENV-1 and DENV-4.

# **Author Summaries**

- Outcomes resulting from dengue mass vaccination remains limited. 54
- 55 Study on Dengvaxia®'s effectiveness in a target population of 501,000 with unknown serostatus.
- Dengue risk reduction was significant for DENV-1 and DENV-4. 56

## Introduction

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

Vector-borne diseases, including dengue, cause approximately 17% of infectious diseases worldwide. It is the fastest-spreading viral infection caused by mosquito bites, endangering 3.97 billion people in 128 countries on nearly every continent, with approximately 400 million infections annually [1]. Incidence rates are highest in South Asia, followed by Southeast Asia, the Caribbean, tropical Latin America, and Central Latin America [2]. In 2022, the Americas reported 2.8 million dengue cases, of which 82% were from Brazil [3]. In the same year, Paraná was Brazil's third most affected state, with an incidence rate of 1,413.6 per 100,000 inhabitants [4].

There is no specific treatment for dengue, and control strategies for its main vector, Aedes aegypti, have presented some limitations [5]. Thus, a vaccine is needed as part of an integrated approach to prevent and control dengue. The first licensed dengue vaccine, Dengvaxia®, developed by Sanofi, was introduced in Brazil in December 2015 for individuals aged 9-44 years [6] as a threedose regimen vaccine with six-month intervals between doses. In clinical trials involving over 30,000 subjects, its overall efficacy against virologically confirmed symptomatic dengue was 65.6% for participants of 9 years of age or older after a 25-month follow-up period. Its efficacy also varied with respect to serotype (DENV-1: 58.4%; DENV-2: 47.1%; DENV-3: 73.6%; DENV-4: 83.2%) [7–9].

This dengue vaccine has been approved in over 20 countries. However, large-scale vaccination campaigns were only organized in Brazil (Paraná state) and the Philippines [6]. The Paraná State Department of Health (SESA/PR) vaccinated free of charge over 300,000 people in 30 municipalities highly affected by dengue between 2016 and 2018, regardless of previous serological status [10], and its effect has been assessed [11]. Hence, we assessed the dengue vaccine's effectiveness in a population-based cohort six years following the launch of the vaccination initiative in Paraná, Brazil.

# Methods

82 Study design and participants

This six-year population-based cohort study focused on a dengue-vaccinated target population residing in 30 municipalities within Paraná state, Brazil, spanning from August 2016 to July 2022.

Paraná is in Brazil's southern region and dengue vaccination was carried out in the municipalities chosen based on epidemiological criteria. The target population in 28 municipalities comprised individuals aged 15-27 and 9-44 years in other two. The vaccination roll-out consisted of five consecutive phases (Table 1) from August 13, 2016, to December 20, 2018, with intervals of approximately six months [10].

Table 1 Dengue vaccination timeline in Paraná, Brazil from 2016 to 2018

Doses administered	Vaccination period
1st dose	August 13 to September 24, 2016
1st dose / 2nd dose	March 1 to April 7, 2017
2 <sup>nd</sup> dose / 3 <sup>rd</sup> dose	September 20 to November 11, 2017
$2^{nd}\;dose\;/\;3^{rd}\;dose$	March 20 to June 29, 2018
3 <sup>rd</sup> dose	November 5 to December 20, 2018
	1st dose  1st dose / 2nd dose  2nd dose / 3rd dose  2nd dose / 3rd dose

Source: SESA/PR

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97


98

99

100

Dengue is a mandatory notification disease, and suspected and confirmed cases nationwide are registered in the National Reportable Disease Information System (Sinan) [12]. Since 1995, dengue has been reported in Paraná, and in recent years, the disease incidence has been the highest ever observed, mainly between 2015-2016 and 2019-2020. Despite this, there is no data on the seroprevalence of the disease in this population. Dengue cases in the 30 municipalities showed a similar pattern to that observed at the state level, with these municipalities accounting for 47.6% of all dengue cases between 2008 and 2016. Four serotypes have circulated in the region since 1995, and DENV-1 has been the most prevalent serotype, except for 2019-2020, in which DENV-2 surpassed the values previously observed for serotype 1 (Figure 1).

Figure 1. Distribution of probable dengue cases in the state of Paraná and the 30 selected municipalities based on the epidemiological weeks (A), and proportion of dengue serotypes identified in the state of Paraná, Brazil (B), between 2008 and 2019.



Source: National Epidemiological Surveillance System (Sinan)

The study population was derived from the population defined by SESA/PR to receive public vaccination and included about 500,000 individuals [10]. These individuals were divided into the vaccinated group, constituted of those who had received any number of dengue vaccine doses, and the non-vaccinated group, comprised of individuals who were eligible for vaccination but were not listed in the vaccinated database. The reference population was obtained by subtracting the number of vaccinated individuals from the target population size.

# **Procedures**

101

102

103

104

105

106

107

108

109

110

111

112

113

114

Exposure variables (vaccinations) were obtained from the SESA/PR vaccine database. They were defined based on the number of vaccine doses received (one, two, or three). A subset of individuals who received three doses in consecutive phases, with an interval of  $\geq$  160 days between doses, was considered to have the complete regimen as recommended and was called the compliance group.

The primary outcome was probable dengue cases (PDC) constituted either by clinical-

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

epidemiological criteria and/or laboratory tests. Secondary outcomes were defined as: i) laboratoryconfirmed dengue; ii) confirmed cases with identified serotypes (DENV-1, 2, 3, and 4); iii) cases with warning signs or severe disease identified based on PDC; and iv) dengue hospitalizations with warning signs or severe disease identified based on PDC.

Control variables included sex, age group, and municipality of residence, which may be associated with adherence to the vaccination schedule and disease risk. Age groups were categorized into 9–14, 15-27, and 28–44 years according to the following criteria: a) individuals aged 15–27 years constituted the target population for vaccination in all 30 municipalities; b) individuals aged 9–14 and 28–44 years constituted the target population for vaccination in only two municipalities.

To identify outcomes in vaccinated patients, the Sinan probabilistic record linkage (PRL) procedure was performed in the SESA/PR vaccination database using OpenRecLink 3.1 [14]. The PRL, with an accuracy of 94.1% (95% CI: 91.9-95.7%) and a Kappa concordance index of 96.1% (95% CI: 95.4–96.8%), was validated in a previous study (unpublished).

According to Table 2, we provided different start times for each exposure variable to define follow-up time in the cohort. Among the vaccinated individuals, follow-up was initiated 30 days after the first vaccine dose was administered (Table 2). Among the non-vaccinated individuals, follow-up was initiated 30 days after the end of the vaccination phase, when approximately 75% of vaccinated individuals had received their respective doses.

Table 2 Initial follow-up date according to the exposure variables for the vaccinated and non-vaccinated groups

	Group					
Exposure variable	Vaccinated	Non-vaccinated				
Any number of doses or a single dose	30th day after the first vaccine dose	October 23, 2016 (30 days after the end of the first phase of vaccination)				
Two doses	30th day after the second vaccine dose	May 7, 2017 (30 days after the end of the second phase of vaccination).				
Three doses or compliant	30th day after the third vaccine dose	December 11, 2017 (30 days after the end of the third phase of vaccination)				

For analytical purposes, the follow-up duration for each participant was extended up to the date

perpetuity. It is made available under a CC-BY 4.0 International license.

of their first confirmed dengue episode in case of disease occurrence. For those who remained denguefree, the predetermined endpoint for follow-up was set at July 31, 2022, with no recorded losses considered in this group.

# Case definitions

Dengue is a mandatorily reportable disease, and the system relies on the notification of all suspected cases of the disease at public and private health facilities based on the initial clinical diagnosis (not laboratory confirmed) [12,15]. The primary outcome was a probable case of dengue (PDC), which includes clinical-epidemiological criteria or laboratory confirmation [13,15], as it is a more sensitive criterion for the diagnosis of dengue and is helpful in the context of epidemiological surveillance of the disease. Laboratory-confirmed dengue was defined as PCR, NS1, or IgM positive test. IgM result was only considered if performed 90 days after any vaccine dose for those vaccinated. *Statistical analysis* 

Incidence rates per 10,000 person-years (IR/10<sup>4</sup>py) and incidence rate ratios (IRR) were calculated for both primary outcomes under consideration. These measures were determined for individuals who received at least one, two, or three vaccine doses or complete regimen as recommended compared to non-vaccinated individuals. Other secondary outcomes were evaluated in patients who received at least one dose.

Poisson regression was used to adjust for confounders, with the time of follow-up used as an offset. Age, sex, and municipality were included in the models. Individuals aged 9–14 and 28–44 years (11.5%) were excluded, except when specific analysis by age group was performed, as they were restricted to only two municipalities.

Vaccine effectiveness and 95% confidence intervals (95% CIs) were calculated using the formula:  $Effectiveness = [1 - IRRa] \times 100$  (eq. 1)

where IRRa is the adjusted incidence rate ratio. Statistical analyses were performed using R 2020 (version 4.0.2) and Stata® (version 15.1) [16,17]. Absolute risk reduction (ARR) and the number

161

162

163

164

165

166

167

168

169

170

171

172

173

necessary for vaccine (NNV) were also calculated and presented for each exposure regimen [18]. For sensitivity analysis, the effectiveness of PDC was evaluated considering the period from 2019 onwards. This study was approved by the Research Ethics Committee of the Federal University of Paraná (N# 2,308,662) and registered in the institution's Integrated Agreement Management System under Process number 23075.040144/2019-49 and published in the DOU on 04/June/ 2020. **Results** This cohort consisted of 501,208 individuals from the vaccination's target population program, 302,603 (60.4%) individuals who received at least one vaccine dose and 198,605 (39.6%) unvaccinated individuals. A total of 142,687 individuals received the three planned doses, among which 122,564 met the compliance criteria. Demographic characteristics and vaccination-related aspects are shown in Table 3. A higher percentage of men received at least one vaccine dose (51.1%) and women had a higher compliance rate (52.4%). The highest frequency of dengue notifications was recorded in 2020 (44.9%).

Table 3. Demographic characteristics, exposure, and dengue notifications in the target population in the 30 municipalities in Paraná from epidemiological week 33/2016 to 52/2019

		Vacci	nated		Non-vacci	inated	Total	
Characteristic	Compl	iant	Total vacc	inated				
	(Total: 12	2,614)	(Total: 30	2,603)	(Total: 19	8,605)	(Total: 501,	208)
	n	%	n	%	n	%	n	%
Sex								
Male	59,914	48.9	158,654	52.4	90,391	45.5	249,045	49.7
Female	62,700	51.1	143,949	47.6	108,214	54.5	252,163	50.3
Age group								
9 to 14*	7,980	6.5	14,409	4.8	4,894	2.5	19,303	3.9
15 to 19	48,718	39.7	111,993	37.0	56,354	28.4	168,347	33.6
20 to 24	32,776	26.7	94,124	31.1	79,822	40.2	173,946	34.7
25 to 27	16,813	13.7	48,509	16.0	52,811	26.6	101,320	20.2
28 to 44*	16,327	13.3	33,568	11.1	4,724	2.4	38,292	7.6
Cohort group								
First	104,484	85.2	205,927	68.1	198,605	100.0	404,532	80.7
Second	18,130	14.8	96,676	31.9			96,676	19.3
Number of doses								
3 doses	122,614	100.0	142,700	47.2			142,700	28.5
2 doses	0		78,337	25.9			78,337	15.6
1 dose	0		81,566	27.0			81,566	16.3
None	0		0		198,605	100.0	198,605	39.6
Notifications								
2016	349	7.9	935	8.4	1,029	7.8	1,964	8.1
2017	831	18.7	2,280	20.6	2,253	17.1	4,533	18.7
2018	533	12.0	1,281	11.6	1,584	12.0	2,865	11.8
2019	2,729	61.4	6,591	59.4	8,300	63.0	14,891	61.4
Total	4,442	100.0	11,087	100.0	13,166	100.0	24,253	100.0

The denominator of the proportions was the total number of individuals in each group (compliant, vaccinated, nonvaccinated, and total cohort). Total vaccinated includes individuals who received any number of vaccine doses. \* For the municipalities of Assaí and Paranaguá, the study population was only composed of the age groups 9-14 and 28-44 years.

174

175

176

177

178

Among the 90,373 notifications recorded from 2016-2022, PDC numbered 50,658, of which 24,219 (47.8%) in the vaccinated group (Table 4). A total of 15,131 (16.7%) were laboratoryconfirmed cases with 8,364 (55.3%) in the vaccinated group. Warning signs were identified in 912 cases, with 520 (57.0%) in the vaccinated group.

Table 4. Probable dengue cases (PDC) in the target population in 30 municipalities in Paraná.

Characteristics		Vaccinated No. 24,219		Non-vacci	inated	Total	
				No. 26,439		No. 50,658	
		N	%	N	%	n	9/
Sex							
Mal		11,969	49.4	12,027	45.5	23,996	47.4
Fem	ale	12,250	50.6	14,412	54.5	26,662	52.0
Age group	144	245		100		0.40	
9 to		745	3.1	198	0.7	943	1.
15 t		10,352	42.7	8,085	30.6	18,437	36.
20 t		7,520	31.1	10,002	37.8	17,522	34.
25 t		3,648	15.1	7,085	26.8	10,733	21.
	o 44*	1,954	8.1	1,069	4.0	3,023	6.
Number of doses				26.420	100.0	26.420	50
Non		0	0	26,439	100.0	26,439	52
1 do		6,487	26.8	0	-	6,487	12
2 do		6,176	25.5	0	-	6,176	12
3 do		11,556	47.7	0	-	11,556	22
Laboratory confirmed ca	ises	22	0.1	25	0.1	577	0
2016				35	0.1	57	
2017		105	0.4	219	0.9	324	0
2018 2019		39	0.1	40	0.2	79	0
2019		1,463 2,765	5.5	1,409 4,082	5.8	2,872 6,847	12
			10.5		16.9		13
2021 2022		1,349 1,024	5.1 3.9	1,502 1,077	6.2 4.4	2,851 2,101	5
Probable dengue cases		1,024	3.9	1,077	4.4	2,101	4
Probable dengue cases 2010		51	0.2	28	0.1	79	0
201		274	1.1	145	0.5	419	0
2013		62	0.3	45	0.2	107	0
2019		2,343	9.7	2,378	9.0	4,721	9
2020		15.478	63.9	16,598	62.8	32,076	63
2021		2,926	12.1	3,208	12.1	6,134	12
202		3.085	12.7	4,037	15.3	7,122	14
Classification of cases	-	2,002		1,027	22.2	,,,,,,	-
Den	gue	23,680	97.8	26,027	98.4	49,707	98
	ming signs	520	2.1	392	1.5	912	1
	ere dengue	19	0.1	20	0.1	39	0
Hospitalization							
Den	gue	389	1.6	318	1.2	707	1
	ming signs	214	0.9	174	0.7	388	0
	ere dengue	16	0.1	18	0.1	34	0
Tota	al identified	619	2.6	510	1.9	1129	2
Laboratory dengue confi	rmed**						
PCI	3	1288	5.3	1197	4.5	2485	4
NS1		4265	17.6	2848	10.8	7113	14
IgM	I	2811	11.6	2722	10.3	5533	10
Any	test (total)	8364	34.5	6767	25.6	15131	29
Identified serotypes							
DE	NV-1	342	1.4	502	1.9	844	1
DE	NV-2	936	3.9	571	2.2	1507	3
DE	NV-4	14	0.1	123	0.5	137	0
Tota	al identified	1292	5.3	1196	4.5	2488	4

The denominator of the proportions was the total number of probable dengue cases in each group (vaccinated, non-vaccinated, and total cases). Total vaccinated: Individuals who received any number of vaccine doses. \*The 9-14 years and 28-44 years age groups constituted the study population only for the municipalities of Assaí and Paranaguá. \*\* Prioritization of the most specific Laboratory test in decreasing order i.e., PCR, NS1, and IgM.

179

180

Thirty-nine severe cases were observed among PDC, 19 in the vaccinated group and 20 in the

182

183

184

185

186

187

188

189

190

non-vaccinated. Dengue-related deaths were reported in both groups during the study period, 5 cases in the vaccinated and 14 occurrences in the non-vaccinated (IR 0.39; 95% CI: 0.14-1.08). Of the 1,129 hospitalizations, 619 (54.0%) were in the vaccinated group, of which 16 (2.6%) involved severe forms, while of the 510 hospitalizations in the non-vaccinated group, 18 (3.5%) were severe.

Vaccine effectiveness on PDC ranged from 31.5% (95% CI: 29.5–33.5) to 35.1% (95% CI: 33.3– 36.8) among those with two doses and those with compliance, respectively (Table 5).

Table 5. Number of probable dengue cases, incidence rates in 10, 000 person-year, crude and adjusted incidence rate ratios, vaccine effectiveness, absolute risk reduction and number needed to vaccinate according to exposure characteristics and primary outcome in 30 municipalities in Paraná.

No.	No. IR No. IR		IRR <sub>e</sub> (95% CI)	IRR <sub>a</sub> (95% CI)	Vaccine Effectiveness (95% CI)	ARR*** (%)	NNV****	
Vaccin	ated**	Non-va	ccinated					
21,520	154.9	25,172	242.0	0.640(0.628 to 0.652)	0.663(0.651 to 0.675)	33.7(32.5 to 34.9)	0.872	115
1 d	lose	Non-va	ccinated					
6,039	157.3	25,172	242.0	0.650(0.632 to 0.669)	0.655 (0.636 to 0.674)	34.5 (32.6 to 36.4)	0.847	118
2 doses Non-vaccinated								
5,623	175.1	25,103	267.5	0.655(0.636 to 0.674)	0.685(0.665 to 0.705)	31.5(29.5 to 33.5)	0.924	108
3 de	3 doses Non-vaccinated		ccinated					
9,858	195.6	25,039	303.0	0.645(0.631 to 0.661)	0.663(0.646 to 0.681)	33.7(31.9 to 35.4)	1.074	93
Compliance Non-vaccinated								
8,459	192.9	25,039	303.0	0.637(0.621 to 0.653)	0.649(0.632 to 0.667)	35.1(33.3 to 36.8)	1.101	91

<sup>\*</sup>IR = Incidence rate/10,000 person-year. IRR.: crude incidence rate ratio calculated using the ratio of incidence rates in each group; IRR. incidence rate ratio adjusted by sex, 15-27 years age group, and municipality of residence; Vaccine Effectiveness was calculated using the adjusted incidence rate ratio in %. \*\* Vaccinated: individuals who received any number of vaccine doses. \*\*\*ARR = Absolute risk reduction. \*\*\*\*NNV = Number needed to vaccinate.

Based on laboratory- confirmed cases, overall effectiveness was 20.1 (95% CI: 17.1-22.9) for at least one dose (Table 6). It ranged from 17.5 (95% CI:12,9-21.9) among those who received two doses to 24.3% (95% CI: 20.1–28.2) for those with one dose.

Table 6. Number of laboratory confirmed dengue cases, incidence rates in 10, 000 person-year, crude and adjusted incidence rate ratios, vaccine effectiveness, absolute risk reduction and number needed to vaccinate according to exposure characteristics and primary outcome in 30 municipalities in Paraná.

No.	IR	No.	IR*	IRR (95% CI)	IRR <sub>a</sub> (95% CI)	Vaccine Effectiveness (95% CI)	ARR*** (%)	NNV****
Vaccin	ated**	Non-va	ccinated					
6,869	51.4	6,074	62.8	0.818(0.790 to 0.847)	0.799 (0.771 to 0.829)	20.1(17.1 to 22.9)	0.142	876
1 d	ose	Non-va	ccinated					
1,817	49.2	6,074	62.8	0.783(0.743 to 0.826)	0.757 (0.718 to 0.799)	24.3 (20.1 to 28.2)	0.136	735
2 do	oses	Non-va	ccinated					
1,810	58.3	6,018	68.7	0.849(0.805 to 0.895)	0.825(0.781 to 0.871)	17.5(12.9 to 21.9)	0.104	966
3 do	oses	Non-va	ccinated					
3,242	66.5	5,987	77.2	0.861(0.825 to 0.899)	0.817(0.777 to 0.858)	18.3(14.2 to 22.3)	0.107	934
Comp	liance	Non-va	ccinated					
2,825	66.6	5,987	77.2	0.863(0.825 to 0.903)	0.806(0.766 to 0.849)	19.4(15.1 to 23.4)	0.106	945

<sup>\*</sup>IR = Incidence rate/10,000 person-year. IRRs: crude incidence rate ratio calculated using the ratio of incidence rates in each group; IRRs: incidence rate ratio adjusted by sex, 15-27 years age group, and municipality of residence; Vaccine Effectiveness was calculated using the adjusted incidence rate ratio in %. \*\* Vaccinated: individuals who received any number of vaccine doses. \*\*\*ARR = Absolute risk reduction. \*\*\*\*NNV = Number needed to vaccinate.

192

193

194

195

196

197

198

199

Higher effectiveness was observed in the 28–44 age group (78.1%; 95% CI: 76.2–79.9%), irrespective of the number of vaccine doses (Table 7). Data for the 28–44 age group were limited to the municipalities of Paranaguá and Assaí. When vaccine effectiveness was stratified by serotype, it was found to be 51.9% (95% CI: 44.6–58.2) and 92.0% (95% CI: 86.2–95.4) for DENV-1 and DENV-4, respectively. No effectiveness was found for DENV-2 (-10.8%; 95% CI: -23.5-0.60), and no DENV-3 cases were reported. Hospitalization was reduced among the vaccinated group (16.5%; CI: 5.5 to 26.3). Dengue cases with warning signs and/or severe forms presented wide confidence intervals for effectiveness, and no definite conclusions may be drawn.

Table 7. Other secondary outcomes, incidence rates in 10, 000 person-year, crude and adjusted incidence rate ratios, vaccine effectiveness, absolute risk reduction and number needed to vaccinate according to exposure characteristics in 30 municipalities in Paraná.

	No.	IR	No.	IR	IRR <sub>c</sub> (95% CI)	IRR <sub>a</sub> (95% CI)	Vaccine Effectiveness (95% CI)	ARR*** (%)	NNT****				
Age groups	Vaccinated**		Vaccinated**		Vaccinated**		Non-vac	cinated					
9 to 14 years	745	91.9	198	71.1	1.292(1.103 to 1.519)	1.090(0.928 to 1.281)	-9.0(-28.1 to 7.2)	-0.201	-				
15 to 27 years	21,520	154.9	25,172	242.0	0.640(0.628 to 0.652)	0,672((0.660 to 0.685)	32.8 (31.5 to 34.0)	0.872	115				
28 to 44 years	1,954	103.4	1,069	425.6	0.243(0.225 to 0.262)	0,219((0.201 to 0.238)	78.1 (76.2 to 79.9)	3.222	31				
Sorotypes	Sorotypes Vaccinated**		Non-vac	cinated									
DENV-1	333	2.5	495	5.2	0.485(0.420 to 0.558)	0.481(0.418 to 0.554)	51.9(44.6 to 58.2)	0.027	4				
DENV-2	836	6.4	546	5.8	1.102(0.988 to 1.230)	1.108(0.994 to 1.235)	-10.8(-23.5 to 0.60)	0.006	17				
DENV-4	14	0.1	123	1.3	0.082(0.044 to 0.143)	0.080(0.046 to 0.139)	92.0(86.2 to 95.4)	0.012	8				
Clinical characteristics	Vaccinated**		Non-vac	cinated									
Alarm/Severe signs	509	3,9	405	4.3	0.905(0.792 to 1.033)	0.901(0.789 to 1.029)	9.9(-2.9 to 21.1)	0.004	25				
Severe dengue	18	0.14	20	0.21	0.648(0.323 to 1.290)	0.588(0.304 to 1.137)	41.2(-13.7 to 69.6)	0.001	133				
Hospitalization	537	3.9	484	4.7	0.830(0.733 to 0.941)	0.835(0.737 to 0.945)	16.5(5.5 to 26.3)	0.008	13				

<sup>\*</sup>IR = Incidence rate/10,000 person-year. IRR: crude incidence rate ratio calculated using the ratio of incidence rates in each group; IRR: incidence rate ratio adjusted by sex and 15-27 years age group; Vaccine Effectiveness was calculated using the adjusted incidence rate ratio in %. \*\* Vaccinated: individuals who received any number of vaccine doses. \*\*\*ARR = Absolute risk reduction. \*\*\*\*NNV = Number needed to vaccinate.

In the sensitivity analysis, 21,252 cases were identified among individuals who received at least one dose (IR 245.2/10<sup>4</sup>py) and 24,993 among non-vaccinated individuals (IR 399.1/10<sup>4</sup>py). The measured vaccine effectiveness was 36.6% (95% CI: 35.4–37.8), similar to that obtained in the primary analysis with PDC.

## **Discussion**

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

In this study, we report the findings on the effectiveness of dengue vaccine, administered in a large population-based cohort in 30 municipalities in Paraná, Southern Brazil [10], after six years of monitoring. Effectiveness was higher among vaccinated individuals but lower than that obtained in efficacy studies [9]. There was significant variability in vaccine effectiveness (VE) for the different viral subtypes; VE was highest for DEN-4 and DEN-1 and lowest for DEN-2 (negative VE values). The VE for serotype 3 could not be evaluated. The high prevalence of serotype 2 during the study period may explain the differences in effectiveness observed here and previous clinical trials. PDC was used as the primary endpoint as it better represents the real scenario of health services in diagnosing dengue in countries like Brazil [18].

Since 2014, when Brazil adopted the WHO classification for dengue, PDC has been the

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

parameter used for dengue disease monitoring through epidemiological surveillance [15]. The signs and symptoms of dengue are well known by health professionals in endemic areas, favoring homogeneity in diagnosing the disease among vaccinated and non-vaccinated individuals. Furthermore, it is crucial to work with probable cases to respond to epidemics promptly, as case confirmation might be expensive and time-consuming [18].

The challenge in anti-dengue vaccine effectiveness studies is defining the primary endpoint. Ideally, this should be based on laboratory-confirmed disease. Laboratory confirmation, however, is not feasible in regions where thousands of suspected cases of dengue occur each year. Therefore, surveillance systems conclude reported cases based on clinical-epidemiological criteria and, anti-dengue vaccine efficacy studies should consider this criterion in their analysis of results.

Dengue notification processes were affected by the outbreak of the large-scale Zika virus in 2014, which spread across the Pacific and reached Brazil, causing an explosive epidemic in South America. Zika infection can be misdiagnosed clinically as Dengue fever, reducing the accuracy of the clinical-epidemiological diagnosis. Moreover, the high genetic similarity between both viruses contributes to a substantial cross-reactivity in the antibody responses, compromising the results of point-of-care serological tests [19].

However, evaluating VE using laboratory methods exclusively presents limitations. Their use depends on the availability of infrastructure and laboratory capacity, making it challenging to offer and apply these procedures universally across municipalities and healthcare sites. Testing rates differed between municipalities, although there was no significant difference in laboratory testing between vaccinated and non-vaccinated individuals. According to De Smedt et al. [20], the laboratory criterion may introduce a differential misclassification bias by underestimating effectiveness, as observed by comparing PDC-based effectiveness estimates with PCRNS1 endpoints. Furthermore, adding IgM tests to the PDC for case identification ratified the primary outcome-based evaluation.

The "exposure to at least one dose" criterion seems the most appropriate because it represents

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

the natural condition of community intervention and reflects population adherence to multiple-dose vaccinations [10]. There was no difference between compliant individuals and those who received the three doses. However, further studies are needed to compare regimens with different numbers of doses, considering different epidemiological contexts [21], the prevalence of circulating serotypes [22], and the change in vaccine recommendations concerning previous seropositivity [23-25]. Effectiveness was higher in older age groups. Since there is a greater probability of previous dengue infection in older individuals, these data corroborate the results of efficacy studies [7,9,26,27]. Although the basal seroprevalence of dengue in Paraná is unknown, a survey of dengue seroprevalence in a Brazilian city with a history of recurrent epidemics showed seropositivity values ranging from 63– 75% in the 10–19 and 40–59 years age groups, respectively [28]. In line with the findings of efficacy studies (CYD14 and CYD15) [9], effectiveness varied according to viral serotype, with the highest values observed for DENV-4 and DENV-1. Notably, global vaccine effectiveness is significantly associated with serotype-related efficacy and depends on identified circulating serotypes, baseline serostatus, and dengue seroprevalence during the study period [22]. All four dengue serotypes have been circulating in Paraná since 1995, including areas where the vaccination campaign was carried out. Throughout the epidemic years spanning from 2008 to 2016, DENV-1 predominated, with minimal circulation of DENV-2 and DENV-4, and negligible presence of DENV-3. However, in 2017, there was an important upsurge in the circulation of DENV-2. In 2019-2020, it was responsible for two-thirds of cases, with a low DENV-1 (37%) and 4 (8%) circulation and the absence of DENV-3 observed. In 2021-2022, there was a rise in the DENV-1 detection, but DENV-2 was predominant [4]. The ineffectiveness of DENV-2 observed in the study population regardless of the serostatus was previously reported by Sabchareon et al. (2012) [29] in a phase IIb Dengvaxia® efficacy study in Thailand and subsequently in the CYD14 and CYD15 studies [30]. The antigenic incompatibility perpetuity. It is made available under a CC-BY 4.0 International license.

between the vaccine virus (Asian-American genotype) and DENV-2 circulating in Southeast Asia (Asian genotype 1) and the unbalanced replication of vaccine viruses is likely responsible for the variability in vaccine effectiveness against different viral types. [31]. Furthermore, Heinen et al. studies indicate that, among children who were seronegative for DENV at baseline, impaired replication of DENV-4 from the tetravalent vaccine stimulates antibodies capable of neutralizing DENV-1 and DENV-3 *in vitro* but not protecting *in vivo* [32].

Further, studies have shown that viruses obtained directly from infected patients' plasma are significantly more infectious than those obtained from cell cultures. Although genotypically identical, DENVs obtained in cell lines are structurally immature and hypersensitive to neutralization by human antibodies compared to DENVs of an infected patient. This phenotypic difference is due to the mature state of the virion obtained in plasma samples compared with immature particles abundantly recovered in cell cultures. In this way, the antibodies induced by the vaccine efficiently neutralize the DENVs in cell culture assays, but they are ineffective in protecting the vaccinated individual [33].

Tetravalent dengue vaccines have been developed on the premise that intra-serotype variability does not interfere with vaccine-generated immune responses. However, in a recent analysis of the genetic diversity of DENV-2 pre-membrane (Pre-M) and envelope (E) proteins, its genotypic variants were evaluated, and were found to be neutralized in different ways by monoclonal antibodies and polyclonal sera derived from DENV-2-infected individuals. They also showed differential responses to antibodies induced by both monovalent dengue 2 vaccines and tetravalent vaccines [34]. Therefore, a high antigenic match between vaccine strains and circulating DENVs may be essential to achieve high vaccine efficacy [30].

A study conducted in Brazil using clinical samples from two cities of São Paulo in 2019, a new genotype, DENV-2 III BR4, was identified. It was probably introduced in Brazil in 2014 and has replaced other DENV-2 strains circulating in the region [35]. However, in this study, we did not perform a molecular analysis of DENV-2 strains circulating in the studied municipalities. Dengue

viruses are constantly under selective pressure, with the consequent emergence of new genotypes that progressively replace previous strains. Thus, the possibility of DENV immune response evasion should be considered in designing vaccines against dengue, which will probably systematically include viral genotypes circulating in the region at that time [22, 29–31, 34]. Therefore, viral genetic surveillance studies are required to understand better the relationship between the vaccine, viral evolution, and

dengue virus genotypic variability.

Vaccine effectiveness was not statistically significant in cases with warning signs, although this outcome was not evaluated in efficacy studies. Few severe cases or warning signs resulted in low accuracy, limiting the assessment of these outcomes. However, it is essential to note that higher incidence rates of hospitalization due to severe cases and warning signs occurred in the non-vaccinated group. The increased risk of hospitalization observed among seronegative participants in follow-up studies led to recommending the vaccine only to seropositive individuals. [24,25]. The results obtained in this study refer to a population with no information about their previous disease situation. Despite this, hospitalization in dengue cases with alarming or severe signs did not pose a greater risk.

The present study was based on a mixed population of dengue-naïve and previously infected individuals when the vaccine was still indicated for all living in regions with high endemicity. From 2018 onwards, the vaccine has only been indicated for people with previous dengue infection (i.e., seropositive) [21]. Therefore, the replication of this study is precluded. Considering future scenarios of effectiveness evaluation, given that the vaccine's efficacy is increased in baseline seropositive subjects the results of studies limited to seropositive populations would potentially be improved compared to this present study.

This study was conducted using secondary databases, which have some limitations. The probabilistic matching of three bases minimized these limitations, allowing us to retrieve individual information with high agreement and accuracy, exclude duplicates, and complement data. Owing to

the data sources used, we could not individually assess the socioeconomic and educational characteristics of the target population, which may be associated with vaccine adherence, health care, and the risk of dengue infection. Studies on factors affecting the acceptance of the dengue vaccine have reported controversial data regarding the effects of socioeconomic status [36,37] and schooling [36–39]. Previous experiences with dengue may also constitute confounding factors, which lead to the vaccination of individuals at a higher risk of developing dengue [37]; however, other studies have not found this association [36,39]. In our study, conditioning for a municipality variable, age, sex, and other characteristics of the municipality are controlled, as they are associated with both the exposure variable (vaccine) and the outcome (notification), minimizing these biases.

The vaccine has proven effective in reducing the incidence of symptomatic dengue in clinical trials, but evidence is lacking regarding the impact it would have on epidemiological surveillance. In this study, we estimated a reduction in reported PDC, representing 33.7% among individuals who received at least one dose of the vaccine.

DENVs are heterogeneous and dynamic, with consequent implications for vaccine research. Recent human natural dengue infection studies have shown that only the presence of anti-DENV antibodies is not enough to define neutralization and protection, as not all neutralizing antibodies are equally protective to the same degree. Therefore, the quality and quantity of anti-DENV neutralizing antibodies are critical. Most importantly, dengue research must focus on understanding DENV immunity and searching for reliable protection markers [40].

The evaluation of effectiveness on laboratory-confirmed cases and serotype-specific infections would have the limitation that the identification of the outcome would be conditioned to a series of known and unknown factors that affect access to diagnosis. These factors can either be a consequence of consultation patterns, also associated with vaccination adherence, or be associated with immunization outcomes (manifestations and disease severity). Thus, there would be a high risk of selection bias when focusing the analysis only on confirmed ones [37]. By estimating the impact of

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

01/view. Accessed Feb 19, 2023.

vaccination on the total PDC, which more sensitively and robustly represents the burden of the disease in the health system, these results become more relevant for planning and actions on public health. **Funding:** This work was supported by Sanofi Pasteur. The funder of this collaborative study, participated in discussing the study's findings and reviewing the manuscript. The authors analyzed and interpreted the data and submitted the manuscript for publication. **Data Availability:** All relevant data are within the manuscript and its Supporting Information files. **Competing interests:** The authors have declared that no competing interests exist. References Vector-borne Available [1] World Health Organization. diseases. at: https://www.who.int/news-room/fact-sheets/detail/vector-borne-diseases . Accessed Feb 19, 2023. Zeng Z, Zhan J, Chen L, Chen H, Cheng S. Global, regional, and national dengue burden from [2] 1990 to 2017: A systematic analysis based on the global burden of disease study 2017. EClinicalMedicine. 2021;32:100712. Pan American Health Organization •. Epidemiological Update for Dengue, Chikungunya and [3] Zika in 2022. Available at: https://www3.paho.org/data/index.php/en/mnu-topics/indicadores-dengueen/annual-arbovirus-bulletin-2022.html. Accessed Feb 19, 2023. Brazilian Ministry of Health/ Health Surveillance Secretariat. Monitoramento dos casos de [4] arboviroses urbanas transmitidas pelo Aedes. Boletim Epidemiológico. 2023;54:1–14. Available https://www.gov.br/saude/pt-br/centrais-deconteudo/publicacoes/boletins/epidemiologicos/edicoes/2023/boletim-epidemiologico-volume-54-no-

- 366 [5] Garcia GdA, David MR, Martins AdJ, Maciel-de-Freitas R, Linss JGB, Araújo SC, et al. The
- impact of insecticide applications on the dynamics of resistance: The case of four Aedes aegypti 367
- populations from different Brazilian regions. PLoS Negl Trop Dis. 2018;12(2): e0006227. 368
- 369 [6] Thomas SJ, Yoon IK. A review of Dengvaxia®: development to deployment. Hum Vaccin
- Immunother. 2019;15:2295-314. 370
- Capeding MR, Tran NH, Hadinegoro SRS, Ismail HIHM, Chotpitayasunondh T, Chua MN, 371 [7]
- 372 et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: A
- phase 3, randomised, observer-masked, placebo-controlled trial. Lancet. 2014;384:1358–65. 373
- 374 [8] Villar L, Dayan GH, Arredondo-García JL, Rivera DM, Cunha R, Deseda C, et al. Efficacy
- 375 of a Tetravalent Dengue Vaccine in Children in Latin America. N Engl J Med. 2015;372:113–23.
- Hadinegoro SR, Arredondo-García JL, Capeding MR, Deseda C, Chotpitayasunondh T, 376 [9]
- 377 Dietze R, et al. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N
- 378 Engl J Med. 2015;373:1195–206. https://doi.org/10.1056/NEJMoa1506223.
- 379 Preto C, Maron de Mello A, Cesário Pereira Maluf EM, Teixeira Krainski E, Graeff G, de [10]
- 380 Sousa GA, et al. Vaccination coverage and adherence to a dengue vaccination program in the state of
- 381 Paraná, Brazil. Vaccine. 2021;39:711-9.
- Moraes JC, Riediger IN, Crosewski F, Garrett DO, Fantinato FF, Ribeiro KB, Luna EJA, A 382 [11]
- case-control study to determine the effectiveness of a tetravalent dengue vaccine in the state of Parana. 383
- 384 Lancet Reg Health Am. 2022;7:100141.
- Coelho GE, Leal PL, Cerroni MdP, Simplicio ACR, Siqueira JB, Jr. Sensitivity of the Dengue 385 [12]
- 386 Surveillance System in Brazil for Detecting Hospitalized Cases. PLoS Negl Trop Dis. 2016;10:
- e0004705. 387
- 388 [13] Hadinegoro SRS. The revised WHO dengue case classification: Does the system need to be
- modified? Paediatr Int Child Health. 2012;32:33-8. 389
- 390 [14] Camargo Jr. KR, Coeli CM. Going open source: some lessons learned from the development

- 391 of OpenRecLink. Cad Saude Publica. 2015;31:257–63.
- 392 [15] Guia de Vigilância em Saúde, 5<sup>a</sup>. edição. Available at: https://www.gov.br/saude/pt-
- br/centrais-de-conteudo/publicacoes/svsa/vigilancia/guia-de-vigilancia-em-393
- saude 5ed 21nov21 isbn5.pdf/view. Accessed in Jan 26, 2022. 394
- R Core Team. (2020). R: A language and environment for statistical computing. R 395 [16]
- Foundation for Statistical Computing, Vienna, Austria. URL https://www.R-project.org/. 396
- Stata Corp (2017). Stata Statistical Software: Release 15. College Station, TX: StataCorp 397 [17]
- 398 LLC.
- Olliaro P, Torreele E, Vaillant M. Covid-19 vaccine efficacy and effectiveness the 399
- 400 elephant (not) in the room. Lancet Microbe. 2021; (published online April 20.).
- 401 Available at: https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(21)00069-0/fulltext.
- Accessed in Feb 19, 2023. 402
- Sharp TM, Anderson KB, Katzelnick LC, Clapham H, Johansson MA, Morrison MA, et al. 403 [17]
- Knowledge gaps in the epidemiology of severe dengue impede vaccine evaluation. Lancet Infect Dis. 404
- 405 2021;12:30871-9
- 406 [18] Angelo M, Ramalho WM, Gurgel H, Bell N, Pillot E. Dengue Surveillance System in Brazil:
- 407 A Qualitative Study in the Federal District. Int J Environ Res Public Health. 2020;2062:2-17.
- Screaton G, Mongkolsapaya J. Which dengue vaccine approach is the most promising, and 408 [19]
- 409 should we be concerned about enhanced disease after vaccination? The challenges of a dengue vaccine.
- 410 Cold Spring Harb Perspect Biol. 2018;10(6):a029520.
- 411 [20] De Smedt T, Merrall E, Macina D, Perez-Vilar S, Andrews N, Bollaerts K. Bias due to
- differential and non-differential disease and exposure misclassification in studies of vaccine 412
- effectiveness. PLoS ONE. 2018;13:1-13. 413
- 414 [21] World Health Organization. Dengue vaccine: WHO position paper – July 2016. Weekly
- 415 Epidemiological Record. 2016;30:349–364.

- [22] Rabaa MA, Girerd-Chambaz Y, Hue KDT, Tuan TV, Wills B, Bonaparte M, et al. Genetic 416
- epidemiology of dengue viruses in phase III trials of the CYD tetravalent dengue vaccine and 417
- implications for efficacy. ELife. 2017;6:1–22. 418
- 419 [23] World Health Organization. Dengue vaccine: WHO position paper – September 2018. Weekly
- 420 Epidemiological Record. 2018;36:457–476.
- Sridhar S, Luedtke A, Langevin E, Zhu M, Bonaparte M, Machabert T, et al. Effect of dengue 421 [24]
- 422 serostatus on dengue vaccine safety and efficacy. N Eng J Med. 2018;379:327–40.
- [25] Wilder-Smith A, Hombach J, Ferguson N, Selgelid M, O'Brien K, Vannice K, et al. 423
- 424 Deliberations of the Strategic Advisory Group of Experts on Immunization on the use of CYD-TDV
- dengue vaccine. Lancet Infect Dis. 2019;19(1):e31-e38. 425
- Dayan GH, Langevin E, Gilbert PB, Wu Y, Moodie Z, Forrat R, et al. Assessment of the 426 [26]
- 427 long-term efficacy of a dengue vaccine against symptomatic, virologically confirmed dengue disease
- 428 by baseline dengue serostatus. Vaccine. 2020;38:3531–6.
- Carabali M, Lim JK, Velez DC, Trujillo A, Egurrola J, Lee KS, et al. Dengue virus serological 429 [27]
- 430 prevalence and seroconversion rates in children and adults in Medellin, Colombia: implications for
- 431 vaccine introduction. Int J Infect Dis. 2017;58:27–36.
- Chiaravalloti-Neto F, Da Silva RA, Zini N, Da Silva GCD, Da Silva NS, Parra MCP, et al. 432 [28]
- Seroprevalence for dengue virus in a hyperendemic area and associated socioeconomic and 433
- 434 demographic factors using a cross-sectional design and a geostatistical approach, state of São Paulo,
- 435 Brazil. BMC Infect Dis. 2019;19:1–14.
- Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, Suvannadabba 436 [29]
- S, et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in 437
- 438 Thai schoolchildren: A randomised, controlled phase 2b trial. Lancet. 2012;380(9853):1559-67.
- doi: 10.1016/S0140-6736(12)61428-7. 439
- Juraska M, Magaret CA, Shao J, Carpp LN, Fiore-Gartland AJ, Benkeser D, et al. Viral 440 [30]

- 441 genetic diversity and protective efficacy of a tetravalent dengue vaccine in two phase 3 trials. Proc
- Natl Acad Sci U S A. 2018;115:E8378-87. 442
- Torresi J, Richmond PC, Heron LG, Qiao M, Marjason J, Starr-Spires L, et al. Replication 443 [31]
- 444 and Excretion of the Live Attenuated Tetravalent Dengue Vaccine CYD-TDV in a Flavivirus-Naive
- 445 Adult Population: Assessment of Vaccine Viremia and Virus Shedding. J Infect Dis. 2017;216:834–
- 41. 446
- 447 [32] Henein S, Adams C, Bonaparte M, Moser JM, Munteanu A, Baric R, et al. Dengue vaccine
- breakthrough infections reveal properties of neutralizing antibodies linked to protection. J Clin Invest. 448
- 449 2021;131(13):e147066.
- 450 [33] Raut R, Corbett KS, Tennekoon RN, Premawansa S, Wijewickrama A, Premawansa G, et al.
- 451 Dengue type 1 viruses circulating in humans are highly infectious and poorly neutralized by human
- 452 antibodies. Proc Natl Acad Sci U S A. 2019;116(1):227-232.
- [34] Martinez DR, Yount B, Nivarthi U, Munt JE, Delacruz MJ, Whitehead SS, et al. Antigenic 453
- Variation of the Dengue Virus 2 Genotypes Impacts the Neutralization Activity of Human Antibodies 454
- 455 in Vaccines. Cell Rep. 2020;33:108226.
- [35] de Jesus JG, Dutra KR, Sales FC da S, Claro IM, Terzian AC, Candido D da S, et al. Genomic 456
- detection of a virus lineage replacement event of dengue virus serotype 2 in Brazil, 2019. Mem Inst 457
- Oswaldo Cruz. 2020;115:2-7. 458
- 459 Harapan H, Anwar S, Setiawan AM, Sasmono RT. Dengue vaccine acceptance and associated [36]
- factors in Indonesia: A community-based cross-sectional survey in Aceh. Vaccine. 2016;34:3670-5. 460
- 461 [37] Hadisoemarto PF, Castro MC. Public Acceptance and Willingness-to-Pay for a Future Dengue
- 462 Vaccine: A Community-Based Survey in Bandung, Indonesia. PLoS Negl Trop Dis. 2013;7(9):1-11.
- Panchapakesan C, Sheldenkar A, Cayabyab YM, Ng JS, Lu J, Lwin MO. A comparison 463 [38]
- 464 between the predictors of vaccine uptake intentions for influenza and dengue. Int J Environ Res Public
- Health. 2018;15:1-10. 465

466 [39] Yeo HY, Shafie AA. The acceptance and willingness to pay (WTP) for hypothetical dengue vaccine in Penang, Malaysia: A contingent valuation study. Cost Eff Resour Alloc. 2018;16:1–10. 467 de Silva AM, Harris E. Which Dengue Vaccine Approach Is the Most Promising, and Should 468 [40] 469 We Be Concerned about Enhanced Disease after Vaccination? The Path to a Dengue Vaccine: Learning from Human Natural Dengue Infection Studies and Vaccine Trials. Cold Spring Harb 470 471 Perspect Biol. 2018;10(6): a029371. Munafo MR, Tilling K, Taylor AE, Evans DM, Smith GD. Collider scope: when selection 472 [41] 473 bias can substantially influence observed associations. Int J Epidem. 2018;47:226–235.

474